IMPORTANCE While amyloid and neurodegeneration are viewed together as Alzheimer disease pathophysiology (ADP), the factors that influence amyloid and AD-pattern neurodegeneration may be considerably different. Protection from these ADP factors may be important for aging without significant ADP.
T he 2 important processes of Alzheimer disease pathophysiology (ADP) are amyloid and neurodegeneration. The widely accepted AD model posits that amyloid accelerates downstream neurodegeneration, which is the underlying substrate of cognitive impairment. 1, 2 While amyloid and neurodegeneration are viewed together as composing ADP, we aimed to test whether protective factors that influence amyloid and AD-pattern neurodegeneration differ. Investigating these factors will enable the development of better prevention strategies to delay the onset and progression of ADP. Although the main AD risk factors are age and APOE genotype, there is no association between APOE genotype and the risk of AD among the oldest elderly individuals. [3] [4] [5] Nelson et al 6 showed that each added year of life does not lead to an increased prevalence of ADP, unlike cerebrovascular disease. Mayo Clinic Study of Aging (MCSA) imaging studies also found nonmonotonicity in the prevalence of amyloid positivity among cognitively normal individuals while the prevalence of cerebrovascular disease monotonically increased with age. 7, 8 Is it possible that a combination of genetic, environmental, and lifestyle factors trigger the onset of ADP among most individuals and that a fraction of the oldest elderly individuals have protection or resistance against ADP despite the aging process? Our second aim was to test whether certain individuals do not have significant ADP in advanced ages because they have protective factors for both amyloid and neurodegeneration. Protective factors against AD dementia can be because of several factors: demographics, APOE, 5,9,10 intellectual enrichment, 11,12 midlife risk factors, [13] [14] [15] [16] [17] [18] [19] and late-life chronic conditions. 20,21 This work's strength is the investigation of all of these protective factors in the context of underlying ADP in a population-based sample to test our hypotheses.
Methods

Selection of Participants
The MCSA is an epidemiological study among Olmsted County, Minnesota residents ages 70 to 89 years. The MCSA enumeration is based on the Rochester Epidemiology Project medical records linkage system. [22] [23] [24] [25] We included 942 elderly individuals with the APOE genotype, intellectual enrichment variables, chronic conditions, risk factors (discussed later), and concurrent Pittsburgh compound B (PiB) and magnetic resonance imaging (MRI) scans. We included the last available PiB and MRI results when individuals had multiple scans. At the time of the scan, 737 patients were cognitively normal, 174 had mild cognitive impairment, 24 received a diagnosis of a neurodegenerative disorder (18 AD, 1 Parkinson disease, 1 AD with vascular dementia, 1 progressive supranuclear palsy, and 3 dementia hard to classify), and 7 had a missing clinical diagnosis because of incomplete data. Peterson et al 26 and Roberts et al 27 describe the MCSA design and diagnosis processes. This study was approved by the Mayo Clinic and Olmsted Medical Center institutional review boards. Written informed consent was obtained from all participants or their surrogates.
Predictor Variables
Demographics and APOE The age and sex of participants were obtained at the clinical visit. We used age at the time of the MRI scan. The presence of the APOE genotype (the presence of APOE ε4 and APOE ε2) was determined from blood collected at clinical visit.
Intellectual Enrichment
We included 3 intellectual enrichment variables: (1) education, (2) job score based on the participant's primary occupation throughout his or her life (intellectually challenging jobs are rated high on a scale of 1-5), 28 and (3) 
Statistical Methods
Standard summary measures were used to describe characteristics for all participants, strata determined by sex, and strata determined by joint categorized amyloid and AD-pattern neurodegeneration status. The results by sex were compared using t tests for continuous variables and χ 2 tests for categorical variables. The amyloid/AD-pattern neurodegeneration results were compared using analyses of covariance (A− vs A+ and N− vs N+) for continuous variables or logistic regressions for categorical variables with an adjustment for age. In sensitivity analyses, we also performed analyses of covariance, allowing for nonlinear age adjustments from spline curves with knots at 75, 80, and 85 years. We used multivariate linear regressions, adjusting for age at MRI, to determine associations of individual predictor variables with continuous measures of amyloid burden and cortical thickness. Amyloid burden was log transformed and subtracted from 0 to meet regression assumptions and to keep the direction of associations consistent with neurodegeneration (positive regression associations being protective). Both outcomes were standardized to z-scores. We used Pillai trace to test if the regression coefficients for the 2 outcomes were simultaneously equal to 0 (no association with both outcomes) for each predictor. We then performed linear regressions, adjusting for age, for each predictor with each outcome. We summarized these results using regression coefficients with their associated standard errors and P values, and statistical significance was set at P < .05. Finally, because amyloid might mediate the effect of the risk factors on cortical thickness, we performed linear regressions, adjusting for age and amyloid, to test for direct effects of the risk factors on neurodegeneration.
Testing the "Exceptional Aging" Hypothesis
To test the "exceptional aging" hypothesis, we considered a subsample of our cohort older than 85 years. Among those individuals, we operationalized exceptional aging without ADP as a subsample of individuals without significant evidence of ADP (ie, A−N−). The key group of interest was the group with A−N− results (ie, the group free of both disease processes). Therefore, we compared the sample of the 85-year-old individuals with A−N− results with those who had either A+, N+, or A+N+ results using t tests for continuous variables and χ 2 tests for categorical variables. Because the sample sizes were small, we also computed Cohen d-based effect size estimations to compare the quantitative strength of each measure in their contribution with exceptional aging.
Results
Participant characteristics are shown in Table 1 . Men had significantly higher education and job scores and women reported higher midlife cognitive activities. A greater percentage of men reported smoking and men had higher CMC scores compared with women. In Table 2 , participants were dichotomized into 4 biomarker groups: A−N−, A+N−, A−N+, and A+N+. Because the 4 groups significantly differed by age, we adjusted the group comparisons for age. Amyloid levels differed by APOE and sex. Midlife dyslipidemia approached statistical significance in predicting amyloid differences by groups (P = .07). Alzheimer disease-pattern neurodegeneration differed by sex, APOE, midlife obesity, smoking, and CMC. Midlife hypertension and dyslipidemia were close to a significant association with neurodegeneration (P >.05toP = .10). Individuals in the groups with N+ results had higher CMC compared with the groups with N− results (median values, 2.8-2.9 [N+] vs 2.3-2.4 [N−]). The more general analyses allowing for a nonlinear age adjustment produced very similar results, exceptthattheP value for AD-pattern neurodegeneration and APOE became marginally greater than .05 (P = .052). Also, eTable 1 in the Supplement shows these differences among cognitively normal individuals to corroborate that the findings were not driven by diagnoses.
Combined and Independent Protective Factors for Amyloid and Neurodegeneration
The results of the multivariate linear regression models are shown in Table 3 . Figure 1 summarizes these findings. The Pillai trace P values determine if the regression coefficients for the 2 outcomes are simultaneously equal to 0 (ie, no association with both outcomes) for each predictor. If significant, then regressions for each outcome can be interpreted. We found that age, sex, APOE genotype, several risk factors, and CMCs were predictors of at least 1 of the outcomes. Older age and the presence of the APOE ε4 allele were associated with higher amyloid deposition. Being male and the presence of the APOE ε2 allele were associated with lower amyloid deposition. Older age, being male, and the presence of an APOE ε4 allele were associated with greater neurodegeneration. However, APOE ε4 association with cor-tical thinning was nonsignificant (P = .58) after adjusting for amyloid (eTable 2 in the Supplement). If amyloid lies between APOE ε4 and cortical thinning on a causal pathway, this would be consistent with an indirect effect of APOE ε4 through amyloid deposition rather than a direct effect on AD-pattern neurodegeneration. Abbreviations: A−, amyloid negative; A+, amyloid positive; N−, neurodegeneration negative; N+, neurodegeneration positive.
a P values for differences between groups are contrasts from an analysis of covariance for the continuous variables or logistic regression for the categorical variables with an adjustment for age with the exception of age, which is unadjusted from an analysis of covariance model. Other than demographics, the protective factors for amyloid and AD-pattern neurodegeneration did not overlap. Increased CMC, midlife diabetes, midlife obesity, and smoking had a significant Pillai trace with cortical thickness as an outcome. On the other hand, midlife dyslipidemia was the only risk factor significantly associated with greater amyloid. Although midlife dyslipidemia approached significance in predicting AD signature thickness (Table 3) , this association was nonsignificant after adjusting for amyloid (eTable 2 in the Supplement). Table 4 describes the characteristics of individuals older than 85 years, dichotomized into [A−N−] 85-year-old individuals with A−N− results without ADP (ie, the exceptional agers) vs those who had A+, or N+, or A+N+ results. The 2 groups differed significantly on the frequency of the presence of the APOE ε4 allele. Midlife dyslipidemia and physical inactivity approached statistical significance between the groups (P < .10). This lack of statistical significance could be because of a lack of differences or a lack of power from the small sample size. The Cohen d results showed small to moderate effects (effect sizes >0.2) for several variables except job score and midlife hypertension. We tested for participation bias among those volunteering for the imaging studies and found some differences (eTable 3 in the Supplement).
Exceptional Aging Hypothesis
Discussion
Our main findings were: (1) the protective factors that influence amyloid and AD-pattern neurodegeneration are different; (2) apart from demographics and APOE genotype, only midlife dyslipidemia was associated with amyloid deposition; and (3) fewer midlife risk factors and chronic conditions, but not intellectual enrichment, may provide significant protection against AD-pattern neurodegeneration.
Protection Against Amyloid Deposition: Age, Sex, APOE, and Midlife Dyslipidemia Age and the APOE genotype are, to our knowledge, the strongest known amyloid risk factors.
9,10,36,37 Our age and APOE findings are consistent with the current literature. There is neuropathological evidence of greater amyloid burden among women compared with men. 38 In Table 1 , the variables that were significantly higher among men compared with women were education level, job score, smoking history, and CMC, but none of these variables were predictors of amyloid ( Table 3) , suggesting that sex differences in amyloid accumulation may be because of unidentified sex-specific mechanisms. Experimental studies have reported that cholesterol accelerates β-amyloid production. 40, 41 Epidemiological studies have asserted that dyslipidemia increases dementia risk.
42
Midlife cholesterol levels are independent AD risk factors in addition to APOE ε4. 43 The association we found here is consistent with these studies. The lack of association after adjusting for amyloid suggests that cholesterol plays an important role in AD pathogenesis via amyloid and not AD-pattern neurodegeneration (eTable 2 in the Supplement). We found that CMC and the other midlife risk factors were not significant predictors of amyloid deposition. While there is some evidence that insulin resistance may predict amyloid deposition, 44 we did not find an association of diabetes and amyloid similar to previous studies. 19, 45 Each of these risk factors has been shown to increase AD dementia risk, which is the sum of the risk for amyloidosis and neurodegeneration. Therefore, the increased risk could be derived from the fact that these midlife risk factors and CMC are catalysts for the neuronal processes but not amyloid deposition, which to our knowledge has not been previously studied.
In Figure 2 , we illustrate that an individual with protection against accumulation of amyloid (eg, absence of the APOE ε4 allele and healthy cholesterol levels) may experience a later elevation in amyloid levels ( Figure 2B ) compared with the average trajectories seen among the population (Figure 2A ). There are 2 components to amyloid trajectories: age at onset and rate of accumulation. While the absence of the APOE ε4 allele may largely contribute to a later age of onset, 9 the protective In Figure 2B , we illustrate an individual with low protection against neurodegeneration using the dashed lines (eg, a greater number of risk factors and CMC). These individuals may have neurodegenerative changes earlier than amyloid and their results for AD-neurodegeneration may be positive while amyloid biomarkers are still under the detection threshold. Recently, individuals with biomarker evidence of neurodegeneration and no amyloidosis were designated with the terminology suspected non-AD pathophysiology, and these individuals who have atrophy in the AD signature regions are more likely to be classified as such.
50,51 These individuals may either be on a separate pathway (eg, vascular or non-AD tauopathy pathway) or may have positive results for amyloid later in life. If they go onto the AD pathway, the time to cognitive impairment will be short and at much lower amyloid levels because of mixed etiologies.
Intellectual Enrichment: Protection Against Cognitive Decline
We found that intellectual enrichment was not a significant predictor of amyloid or AD-pattern neurodegeneration. Our work previously showed that the effect of intellectual enrichment on AD biomarkers may be minimal but that it has a larger effect on delaying the onset of cognitive impairment, 12,52 suggesting that it is mainly protective against cognitive decline.
Is "Exceptional Aging" Without ADP Possible?
The main risk factors for AD are age, genetics, lifestyle, midlife risk factors, and CMC. The absence of ADP among "exceptional aging" individuals may be explained by survival bias and genetic profiles. [53] [54] [55] [56] However, recent literature supported the fact that risk factors and behaviors throughout the lifespan may influence AD pathology, 57-63 which is supported by neuropathological literature that found that some individuals with APOE ε4 will not develop AD dementia even over the lifespan. 3 ,4,64 Although we did not detect clear differences in Table 4 , the small-to moderate-effect sizes of several predictors suggests that protection against both amyloid and ADpattern neurodegeneration is important. If protection against AD pathology in each individual were to be viewed as a "net sum" of effects from aging, genetics (net difference between protective and risk genes), lifestyle, midlife risk factors, and CMC, then "exceptional aging" without ADP in individuals is possible if a large positive "net sum" were present. The absence of midlife risk factors and lower CMC may be important for a positive "net sum." Steadily falling dementia incidence 65 and declining amyloid deposition in aging brains 66 provide evidence for the possibility of "exceptional aging."
Strengths and Limitations
A strength of this study was our large population-based sample with imaging biomarkers. Our study also had several limitations. First, we focused on a limited number of protective factors. Second, the group with A−N− results had a lower mean age than the groups with A+ and N+ results. It is possible that some participants with A−N− results would have A+ or N+ results within a few years. The groups were thus not as distinct as in a non-population based sample in which the groups were age matched. Third, neurodegeneration in AD-susceptible regions is a surrogate of AD tau pathology 67 and thus was used in this study. However, future studies will benefit from using tau-PET imaging assessment for the direct assessment of tau burden. Finally, while we found evidence for exceptional aging without ADP, future studies will need to further investigate how the cumulative sum of positive and negative factors across the lifespan may contribute to the risk of amyloidosis and neurodegeneration.
Conclusions
We found that the protective factors that influence amyloid and AD pattern neurodegeneration are different. We found the "exceptional aging" without ADP may be possible with a greater number of protective factors across the lifespan, but this warrants further investigation. 
